메뉴 건너뛰기
Leukemia Research
Volumn 33, Issue 8, 2009, Pages
Lenalidomide-induced durable hematological and cytogenetic remission in del(5q)-associated de novo acute myeloid leukemia
Author keywords

[No Author keywords available]
Indexed keywords

ANTIBIOTIC AGENT; LENALIDOMIDE;
EID: 67349190564     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.02.026     Document Type: Letter
Times cited : (1)
References (7)
  • 1
    • 63349101923 scopus 로고    scopus 로고
    • Hematologic and cytogenetic response to lenalidomide in de novo acute myeloid leukemia with chromosome 5q deletion
    • Peñarrubia M.J., Silvestre L.A., Conde J., Cantalapiedra A., and Garcia Frade L.J. Hematologic and cytogenetic response to lenalidomide in de novo acute myeloid leukemia with chromosome 5q deletion. Leuk Res 33 (2009) e8-e9
    • (2009) Leuk Res , vol.33
    • Peñarrubia, M.J.1    Silvestre, L.A.2    Conde, J.3    Cantalapiedra, A.4    Garcia Frade, L.J.5
  • 2
    • 33749438404 scopus 로고    scopus 로고
    • Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
    • List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355 (2006) 1456-1465
    • (2006) N Engl J Med , vol.355 , pp. 1456-1465
    • List, A.1    Dewald, G.2    Bennett, J.3
  • 3
    • 33747167338 scopus 로고    scopus 로고
    • Lenalidomide therapy in myelofibrosis with myeloid metaplasia
    • Tefferi A., Cortes J., Verstovsek S., et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 108 (2006) 1158-1164
    • (2006) Blood , vol.108 , pp. 1158-1164
    • Tefferi, A.1    Cortes, J.2    Verstovsek, S.3
  • 4
    • 34447634117 scopus 로고    scopus 로고
    • Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions
    • Tefferi A., Lasho T.L., Mesa R.A., Pardanani A., Ketterling R.P., and Hanson C.A. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia 21 (2007) 1827-1828
    • (2007) Leukemia , vol.21 , pp. 1827-1828
    • Tefferi, A.1    Lasho, T.L.2    Mesa, R.A.3    Pardanani, A.4    Ketterling, R.P.5    Hanson, C.A.6
  • 5
    • 33750327898 scopus 로고    scopus 로고
    • Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome
    • Mesa R.A., Tefferi A., Li C.Y., and Steensma D.P. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome. Leukemia 20 (2006) 2063-2064
    • (2006) Leukemia , vol.20 , pp. 2063-2064
    • Mesa, R.A.1    Tefferi, A.2    Li, C.Y.3    Steensma, D.P.4
  • 6
    • 33847214959 scopus 로고    scopus 로고
    • Treatment of deletion 5q acute myeloid leukemia with lenalidomide
    • Lancet J.E., List A.F., and Moscinski L.C. Treatment of deletion 5q acute myeloid leukemia with lenalidomide. Leukemia 21 (2007) 586-588
    • (2007) Leukemia , vol.21 , pp. 586-588
    • Lancet, J.E.1    List, A.F.2    Moscinski, L.C.3
  • 7
    • 1542753559 scopus 로고    scopus 로고
    • Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
    • Cheson B.D., Bennett J.M., Kopecky K.J., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21 (2003) 4642-4649
    • (2003) J Clin Oncol , vol.21 , pp. 4642-4649
    • Cheson, B.D.1    Bennett, J.M.2    Kopecky, K.J.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.